MX2022015165A - Formas y composiciones de un agonista beta adrenégico. - Google Patents

Formas y composiciones de un agonista beta adrenégico.

Info

Publication number
MX2022015165A
MX2022015165A MX2022015165A MX2022015165A MX2022015165A MX 2022015165 A MX2022015165 A MX 2022015165A MX 2022015165 A MX2022015165 A MX 2022015165A MX 2022015165 A MX2022015165 A MX 2022015165A MX 2022015165 A MX2022015165 A MX 2022015165A
Authority
MX
Mexico
Prior art keywords
forms
compositions
beta adrenergic
adrenergic agonist
beta
Prior art date
Application number
MX2022015165A
Other languages
English (en)
Spanish (es)
Inventor
Wei Chen
David Scott Carter
Bing Xue
Original Assignee
Curasen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curasen Therapeutics Inc filed Critical Curasen Therapeutics Inc
Publication of MX2022015165A publication Critical patent/MX2022015165A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/06—Glycolic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50—Mandelic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/06—Saturated compounds having a carboxyl group bound to a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/90—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl and carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022015165A 2020-06-04 2021-06-03 Formas y composiciones de un agonista beta adrenégico. MX2022015165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063034900P 2020-06-04 2020-06-04
PCT/US2021/035796 WO2021247934A1 (en) 2020-06-04 2021-06-03 Forms and compositions of a beta adrenergic agonist

Publications (1)

Publication Number Publication Date
MX2022015165A true MX2022015165A (es) 2023-03-01

Family

ID=78829944

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015165A MX2022015165A (es) 2020-06-04 2021-06-03 Formas y composiciones de un agonista beta adrenégico.

Country Status (9)

Country Link
US (1) US20230219892A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161496A4 (cg-RX-API-DMAC7.html)
JP (1) JP7734700B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230021075A (cg-RX-API-DMAC7.html)
CN (1) CN115989019B (cg-RX-API-DMAC7.html)
AU (1) AU2021282582A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179993A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022015165A (cg-RX-API-DMAC7.html)
WO (1) WO2021247934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11607395B2 (en) 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
JP2023541379A (ja) * 2020-09-01 2023-10-02 キュラセン セラピューティクス インコーポレイテッド 神経系の疾患及び障害を改善するための組成物及び方法
US12616667B2 (en) 2021-11-15 2026-05-05 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
CN120583945A (zh) 2023-01-20 2025-09-02 阿托基公司 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
WO2003072573A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
WO2011133226A2 (en) 2010-04-22 2011-10-27 The Board Of Trustees Of The Leland Stanford Junior University Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
BR112013012994A2 (pt) * 2010-11-24 2016-09-13 Lithera Inc formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno
US9320724B2 (en) 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
US9889087B2 (en) 2014-06-10 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor
BR112018073227A2 (pt) * 2016-05-13 2019-02-19 The Board Of Trustees Of The Leland Stanford Junior University compostos moduladores do receptor adrenérgico e métodos de uso do mesmo
WO2018169742A1 (en) * 2017-03-14 2018-09-20 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibtor
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
EP3806957A4 (en) * 2018-06-14 2022-03-16 Curasen Therapeutics, Inc. METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
US10947196B2 (en) * 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Also Published As

Publication number Publication date
CN115989019B (zh) 2026-01-02
EP4161496A1 (en) 2023-04-12
KR20230021075A (ko) 2023-02-13
CN115989019A (zh) 2023-04-18
JP7734700B2 (ja) 2025-09-05
EP4161496A4 (en) 2024-08-21
US20230219892A1 (en) 2023-07-13
CA3179993A1 (en) 2021-12-09
AU2021282582A1 (en) 2023-02-02
JP2023528450A (ja) 2023-07-04
WO2021247934A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
MY209784A (en) Heterocyclic compound and use thereof
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
MX2023013978A (es) Composicion fungicida que contiene compuestos de oxadiazol.
MX2025015186A (es) Inhibidores de pi3k y uso de estos
PH12020551304A1 (en) Novel crystalline forms
UA96450C2 (ru) Азолилметилоксираны, их применение для борьбы с фитопатогенными грибами, средство для защиты растений, способ борьбы с фитопатогенными грибами и посевной материал
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
TN2011000222A1 (en) Melanocortin receptor agonists
MX2020007562A (es) Nuevas antranilamidas, su uso como insecticida y procesos para su preparacion.
PY2071938A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
SG11201806682TA (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
MX2025000174A (es) Compuestos y metodos terapeuticos.
DE602004024383D1 (de) Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists
MX2020006370A (es) Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas.
MX2018001902A (es) Aditivo para composiciones lubricantes que comprenden un compuesto de organomolibdeno que contiene azufre y sin azufre y un triazol.
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
NZ782087A (en) Feed composition comprising hexahydro-β-acid component compounds and application thereof
PH12022550859A1 (en) 2-azaspiro[3.4]octane derivatives as m4 agonists
PH12020551330A1 (en) Insecticidal composition and use thereof
CL2021000302A1 (es) Proceso para la preparación de estimuladores de guanilato ciclasa soluble. (divisional de solicitud 202002283).
MX2021004085A (es) El uso de un agonista inverso de h3r para el tratamiento de la somnolencia diurna excesiva asociada con la enfermedad de parkinson (ep).
TW200716607A (en) Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
ZA202006181B (en) Process for the preparation of iloprost
WO2023278403A3 (en) Crystalline hydrochloride salts of substituted tryptamines
MX2023007382A (es) Composiciones y métodos relacionados con compuestos que contienen biciclo [2.2.1] heptanamina di-sustituida.